The first patient has been dosed in Anavex Life Sciences’ Phase 2 trial evaluating Anavex 2-73 for the treatment of Rett syndrome. The trial (NCT03758924) assessing the safety, tolerability, and efficacy of Anavex 2-73 in 15 adults (18 and older) with Rett syndrome is going on at three clinical sites in the…
News
Genetic screening for mosaic mutations — those present in only some cells in the body — may be useful to understand disease development and severity in patients with Rett syndrome and other rare genetic disorders, a case report study says. The study, “De novo mosaic MECP2 mutation in a…
A new study reports an increasing trend in the number of prenatal genetic tests to detect spontaneous mutations that can cause conditions such as Rett syndrome. The study, “Prenatal diagnosis for de novo mutations: Experience from a tertiary center over a 10‐year period,” was published in Molecular…
Madeline Collin, a 24-year-old activist with Gaucher disease, worries that patients like her will suffer deeply if Britain leaves the European Union (EU), as scheduled, at the end of this month. Collin is an expert on the subject. For her University of Bathdissertation, she analyzed Brexit’s long-term impact…
With each new advance in medicine comes ethical dilemmas, from fertility treatments and newborn screening, to vaccinations, gene therapies and euthanasia. But rare diseases and the expensive therapies needed to treat them — particularly in an age of scarce economic resources — almost always entail “tragic choices,” warned Avraham Steinberg,…
Rare diseases affect about 30 million Americans — roughly the same number as those with type 2 diabetes. Yet only 5 percent of the estimated 7,000 rare diseases known to science have cures or treatments approved by the U.S. Food and Drug Administration (FDA). Raising awareness of those illnesses and highlighting…
Researchers have discovered the genetic mechanisms involved in female inheritance and X chromosome silencing. This process, known as X chromosome inactivation, can potentially be manipulated for the treatment of disorders arising from defects in the X chromosome, including fragile X syndrome and Rett syndrome, a study reports. The…
Proteomic analysis — the characterization of all the proteins present in a cell at a given time — has revealed that a misregulation in the development of neural progenitor cells (NPCs), which eventually give rise to different types of nerve cells, might be implicated in Rett syndrome.
The world’s biggest gathering of rare disease researchers, patient groups, pharmaceutical executives, and government officials is planned for April 10–12 in a Washington, D.C., suburb. Some 1,200 people have already registered to attend the World Orphan Drug Congress (WODC) USA 2019, set to take place at the Gaylord National Harbor…
Rettsyndrome.org is dedicated to funding research in every stage of development and every aspect of Rett syndrome — that’s the main message from a recent webinar hosted by Steve Kaminsky, PhD, the organization’s chief science officer. The webinar, along with other RettEd webcasts, can be found here.
Recent Posts
- FDA approves Daybue Stix, drug’s powdered formulation, for treating Rett
- My youngest daughter has now lived longer than her older sister did
- Severe epilepsy increases care needs for people with Rett
- Gene therapy NGN-401 leads to functional gains in Rett syndrome
- New study links Rett energy problems to specific gene mutations
- A Rett syndrome clinical trial was our way of paying it forward
- Partners to design AI-based gene editing therapies for Rett
- Rett gene therapy trial starts dosing patients
- Iron-fueled death of cells may drive Rett syndrome damage: Study
- How Rett syndrome affected my children’s birth order traits